Trastuzumab rezetecan: HER2-mutated non-small cell lung cancer: consultation records checklist

1. Bring lung cancer pathology and the complete HER2/ERBB2 genetic report to confirm an activating mutation
2. Organise previous medicines, responses and reasons for stopping to assess whether the evidence matches your treatment history
3. Provide recent original chest CT images and pneumonitis history for lung toxicity risk assessment
4. Prepare blood counts, liver and kidney tests and current medicines to plan safety monitoring

Questions to clarify
- Do I meet the eligibility criteria?
- What are the separate medical and coordination service costs without Chinese health insurance or free-drug assistance?
- How are initial treatment, ongoing treatment, return travel and follow-up arranged?
- Which risks require immediate contact with the hospital?

An initial service consultation does not replace medical assessment.